PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer : real-world data from Italian molecular pathology laboratories
Introduction: PIK3CA gene mutations occur in approximately 40% of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancers (MBCs), electing them to targeted therapy. Testing PIK3CA status is complex due to selection of biological specimen and testing method. Materials & methods: This work investigates real-life experience on PIK3CA testing in HR+/HER2- MBC. Clinical, technical and molecular data on PIK3CA testing were collected from two referral laboratories. Additionally, the results of a nationwide PIK3CA survey involving 116 institutions were assessed. Results: Overall, n = 35 MBCs were PIK3CA-mutated, with mutations mostly occurring in exons 9 (n = 19; 51.4%) and 20 (n = 15; 40.5%). The nationwide survey revealed significant variability across laboratories in terms of sampling methodology, technical assessment and clinical report signing healthcare figures for PIK3CA molecular testing in diagnostic routine practice. Conclusion: This study provides insights into the real-world routine of PIK3CA testing in HR+/HER2- MBC and highlights the need for standardization and networking in predictive pathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 25(2024), 3 vom: 05. Feb., Seite 161-169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pepe, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2023-0238 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369306937 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369306937 | ||
| 003 | DE-627 | ||
| 005 | 20240323001020.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0238 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM369306937 | ||
| 035 | |a (NLM)38440825 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pepe, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer |b real-world data from Italian molecular pathology laboratories |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: PIK3CA gene mutations occur in approximately 40% of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancers (MBCs), electing them to targeted therapy. Testing PIK3CA status is complex due to selection of biological specimen and testing method. Materials & methods: This work investigates real-life experience on PIK3CA testing in HR+/HER2- MBC. Clinical, technical and molecular data on PIK3CA testing were collected from two referral laboratories. Additionally, the results of a nationwide PIK3CA survey involving 116 institutions were assessed. Results: Overall, n = 35 MBCs were PIK3CA-mutated, with mutations mostly occurring in exons 9 (n = 19; 51.4%) and 20 (n = 15; 40.5%). The nationwide survey revealed significant variability across laboratories in terms of sampling methodology, technical assessment and clinical report signing healthcare figures for PIK3CA molecular testing in diagnostic routine practice. Conclusion: This study provides insights into the real-world routine of PIK3CA testing in HR+/HER2- MBC and highlights the need for standardization and networking in predictive pathology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PIK3CA | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a molecular testing | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Class I Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 650 | 7 | |a PIK3CA protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 700 | 1 | |a Venetis, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Cursano, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Frascarelli, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Pisapia, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Vacirca, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Scimone, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Rappa, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Mane, Eltjona |e verfasserin |4 aut | |
| 700 | 1 | |a Pagni, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Castellano, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Troncone, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Angelis, Carmine De |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Guerini-Rocco, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Malapelle, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Fusco, Nicola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 25(2024), 3 vom: 05. Feb., Seite 161-169 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:05 |g month:02 |g pages:161-169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0238 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 3 |b 05 |c 02 |h 161-169 | ||